Stagnant NCI Funding Has Slowed Cancer Research

Long-term funding levels for NCI-sponsored clinical trials have impacted the pace at which cancer research moves forward.

Updated on Oct. 12, 2026 in Cancer

Stagnant NCI Funding Has Slowed Cancer Research

Live Poll

Should the federal government increase funding for NCI-sponsored cancer clinical trials?

Funding for NCI-sponsored trials has remained unchanged for over two decades, leading to decreased participation in these critical studies. This stagnation challenges the speed of cancer research across the United States.

Why it matters

Clinical trials are essential for advancing cancer treatments, yet sites are becoming more reluctant to open NCI-sponsored studies due to insufficient financial support. This shifts the focus of many facilities toward pharmaceutical-sponsored research instead.

Official reports indicate that funding for NCI-sponsored clinical trials, which are typically Phase 2 or Phase 3 studies, has remained flat for 20 years. The long-term impact on research recruitment rates remains under investigation.

The players

National Cancer Institute

The federal agency that sponsors essential Phase 2 and Phase 3 clinical trials and manages Cancer Center Support Grants.

The details

NCI-sponsored trials are foundational to cancer research and are directly tied to Cancer Center Support Grants, which facilities require to maintain their official designation. Because NCI funding has not increased, many sites have turned to pharmaceutical-sponsored studies to balance their portfolios and cover operational costs. These private trials are prioritized by companies based on business goals rather than the public health needs typically served by NCI-funded studies.

September 24-25, 2026: The Patient-Centered Oncology Care 2026 conference was held in Nashville.

Health Landscape

This stagnation sits in direct contrast to the intended purpose of the National Cancer Institute's Cancer Center Support Grants to facilitate robust research. It reflects a widening gap between public research objectives and the shifting financial landscape of oncology clinical trials.

If you are considering participating in a clinical trial, you may notice that fewer options are available at your local NCI-designated center. Discuss with your physician whether a specific trial is sponsored by the NCI or a private entity to better understand the research goals.

The takeaway

Flat funding for federal cancer research trials is currently slowing the pace of new study openings and patient enrollment. Patients interested in trial options should talk to their oncology team about the types of studies currently open at their facility.